Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	3	42,175	N/A	N/A	82.91% (50.49% to 94.10%)
Severe or critical COVID‐19 after complete vaccination	1	25,452	N/A	N/A	100.00% (86.99% to 100.00%)
All‐cause mortality	1	29,582	Risk Ratio (M‐H, Random, 95% CI)	0.90 (0.30 to 2.68)	N/A
Serious adverse events	4	46,202	Risk Ratio (M‐H, Random, 95% CI)	0.92 (0.74 to 1.14)	N/A
Systemic reactogenicity events	3	31,063	Risk Ratio (M‐H, Random, 95% CI)	1.21 (1.17 to 1.25)	N/A
Any adverse event	5	46,231	Risk Ratio (M‐H, Random, 95% CI)	1.15 (1.05 to 1.26)	N/A
Local reactogenicity events	3	31,063	Risk Ratio (M‐H, Random, 95% CI)	2.78 (1.99 to 3.88)	N/A